LYL-845 is under clinical development by Lyell Immunopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LYL-845’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LYL-845 is under development for the treatment of solid tumor, relapsed and refractory metastatic melanoma, relapsed and refractory non-small cell lung cancer and relapsed and refractory metastatic colorectal cancer. The therapeutic candidate comprises autologous, tumor-infiltrating lymphocytes (TIL). It is administered through the intravenous route. It is being developed based on an ex vivo epigenetic reprogramming (Epi-R) technology platform.
Lyell Immunopharma overview
Lyell Immunopharma (Lyell) is a biotechnology company developing cell-based immunotherapies for solid tumors and other cancers. It provides effective cell therapy is the profound understanding of the identity, fate, and function of cells to create living medicines. The company focuses on controlling and improving the differentiation and functionality of T cells armed with TCRs (T-cell receptor), CARs (chimeric antigen receptor), and other targeting modalities. Lyell ‘s effective cell therapy is the deep and profound understanding of the identity, fate and function of cells to create living medicines. The company operates an office in Seattle, Washington, the US. Lyell is headquartered in South San Francisco, California, the US.
For a complete picture of LYL-845’s drug-specific PTSR and LoA scores, buy the report here.